This article was downloaded by: [McGill University Library] On: 04 February 2015, At: 04:39 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



# Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lncn19

# Synthesis of 3'-Amino and 5'-Amino Hydantoin 2'-Deoxynucleosides

Ahmed A. El-Barbary  $^{\rm a\ c}$  , Ahmed I. Khodair  $^{\rm a\ c}$  , Erik B. Pedersen  $^{\rm a\ \&}$  Claus Nielsen  $^{\rm b}$ 

<sup>a</sup> Department of Chemistry, Odense University, DK-5230, Odense M, Denmark

<sup>b</sup> Retrovirus Laboratory, Department of Virology, Statens Seruminstitut, Artillerivej 5, DK-2300, Copenhagen, Denmark

<sup>c</sup> Chemistry Department, Faculties of Science and Education, Tanta University, Tanta, Egypt

Published online: 23 Sep 2006.

To cite this article: Ahmed A. El-Barbary , Ahmed I. Khodair , Erik B. Pedersen & Claus Nielsen (1994) Synthesis of 3'-Amino and 5'-Amino Hydantoin 2'-Deoxynucleosides, Nucleosides and Nucleotides, 13:1-3, 707-717, DOI: <u>10.1080/15257779408013274</u>

To link to this article: http://dx.doi.org/10.1080/15257779408013274

### PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

Conditions of access and use can be found at <a href="http://www.tandfonline.com/page/terms-and-conditions">http://www.tandfonline.com/page/terms-and-conditions</a>

### SYNTHESIS OF 3'-AMINO AND 5'-AMINO HYDANTOIN 2'-DEOXYNUCLEOSIDES<sup>†</sup>

Ahmed A. El-Barbary,<sup>a,#</sup> Ahmed I. Khodair,<sup>a,#</sup> Erik B. Pedersen,<sup>a,\*</sup> and Claus Nielsen<sup>b</sup>

<sup>a</sup>Department of Chemistry, Odense University, DK-5230 Odense M, Denmark. <sup>b</sup>Retrovirus Laboratory, Department of Virology, Statens Seruminstitut, Artillerivej 5, DK-2300 Copenhagen, Denmark

**Abstract:** 3'-Amino and 5'-amino derivatives of hydantoin 2'-deoxynucleosides have been prepared from the corresponding 3'-phthalimido and 5'-azido nucleosides, respectively, which in turn were prepared by condensation of appropriate sugars with 5benzylidenehydantoin. The amino nucleosides were tested for their potential activity against HIV and HSV.

Recently, we have shown that hydantoin analogues of thymidine are easily synthesized by condensing a silylated hydantoin derivative with an appropriately protected 2-deoxy pentofuranoside in the presence of trimethylsilyl trifluoromethanesulfonate (TMS triflate)<sup>1</sup>. In continuation of this work we found it interesting to synthesize 3'-amino and 5'-amino nucleosides with a hydantoin moiety as the nucleobase because the corresponding thymidine analogues for a long time have been known for their interesting biological properties. The 5'-amino analogue of thymidine is a good competitive inhibitor of the phosphorylation of thymidine by thymidine kinase<sup>2,3</sup> and a modest inhibitor of thymidylate kinase.<sup>4</sup> The interest in amino analogues of nucleosides in general was stimulated by

<sup>&</sup>lt;sup>†</sup>This paper is dedicated to the memory of Professor Roland K. Robins.

<sup>&</sup>lt;sup>#</sup>On leave from Chemistry Department, Faculties of Science and Education, Tanta University, Tanta, Egypt.

the findings that the 5'-amino analogues of thymidine and 5-iodo-2'-deoxyuridine have significant antiviral activity.<sup>5-8</sup> The 5'-amino analogue of thymidine was inhibiting for 98% the replication of Herpes Simplex Virus (HSV-1) in cell culture at 400  $\mu$ M.<sup>8</sup> The 3'-amino analogue of thymidine, however, exerted a modest 62% inhibition of HSV-1 replication at 400  $\mu$ M in Vero cells, while the proliferation of murine sarcoma 180 cells and of murine leukemia L1210 cells is inhibited for 50% at 5  $\mu$ M and 1  $\mu$ M, respective-ly.<sup>8</sup> The 5'-amino analogue is a good antiviral agent but a poor antineoplastic agent, whereas the 3'-amino analogue is an excellent antineoplastic agent but a poor antiviral agent.<sup>8</sup>



The syntheses of the synthons 4 and 5 for preparation of 3'-amino and 5'-amino hydantoin nucleosides are shown above. Treatment of 2-deoxy-D-ribose (1) with hydrogen chloride in methanol<sup>9</sup> afforded methyl 2-deoxy-D-*erythro*-pentofuranoside 2. Replacement of 5-OH in 2 with an azido group was accomplished by treatment with sodium azide, carbon tetrabromide and triphenylphosphine in *N*,*N*-dimethyl formamide at room temperature.<sup>10</sup> Subsequent reaction of 3 with p-toluoyl chloride in pyridine afforded the corresponding methyl 5-azido-3-*O*-(4-methylbenzoyl)-2,5-dideoxy- $\beta$ -D-*erythro*-pentofuranoside (4 $\beta$ ) and its corresponding  $\alpha$  anomer (4 $\alpha$ ) in the ratio 3:4. The preparation of the other synthon, 1,5-di-*O*-acetyl-2,3-dideoxy-3-phthalimido- $\beta$ -D-*erythro*-pentofuranose

#### **HYDANTOIN 2'-DEOXYNUCLEOSIDES**

(5), has already been reported starting from 1 by use of a phthalimide /  $P_4O_{10}$  /  $H_2O$  / n-Bu<sub>4</sub>N reagent in chloroform followed by acetylation.<sup>11</sup>



Silylation of 5-(phenylmethylene)-2,4-imidazolidinedione 6 was accomplished with 1,1,1,3,3,3-hexamethyldisilazane (HMDS) in the presence of a catalytic amount of ammonium sulphate. The trimethylsilylated derivative thus obtained was condensed with methyl 5-azido-3-*O*-(4-methylbenzoyl)-2,5-dideoxy- $\alpha$ -D-*erythro*-pentofuranoside (4 $\alpha$ ) when left overnight in the presence of trimethylsilyl trifluoromethanesulfonate (TMS triflate) at -30°C. Each of the nucleosides 7 and 8 ( $\alpha/\beta = 1:1$ ) were isolated by silica gel chromatography in 22% yield. Removal of the protecting toluoyl group from the sugar moiety of 7 and 8 was achieved by treatment with sodium methoxide in methanol at room temperature and (*Z*)-1-(5-azido-2,5-dideoxy- $\beta$ -D-*erythro*-pentofuranosyl)-5-(phenylmethyl-ene)-2,4-imidazolidinedione (9) and the corresponding  $\alpha$  anomer 10 were obtained, respectively. Treatment of 9 with tin(II)chloride in methanol afforded the corresponding 5'-amino derivative 11 in 10% yield.

1,5-Di-O-acetyl-2,3-dideoxy-3-phthalimido- $\beta$ -D-erythro-pentofuranose (5) was



similarly condensed with the trimethylsilyl derivative of 6 in the presence of TMS triflate on standing overnight at -30°C. The nucleosides 12 and 13 ( $\alpha/\beta = 4:5$ ) were isolated by silica gel chromatography. Removal of the protecting phthaloyl group from the glycon moiety of 12 and 13 was performed with methyl amine in absolute ethanol at room temperature to furnish (Z)-1-(3-amino-2,3-dideoxy- $\beta$ -D-*erythro*-pentofuranosyl)-5-(phenylmethylene)-2,4-imidazolidinedione (14) and its corresponding  $\alpha$  anomer 15.

The compounds 10 and 13 were selected for <sup>1</sup>H NOE difference spectroscopy to assign the anomeric configuration, site of glycosylation on the hydantoin ring, and Z configuration of the exocyclic double bond. The protons in the <sup>1</sup>H-NMR spectra were assigned by <sup>1</sup>H-<sup>1</sup>H-homonuclear shift correlated (COSY) 2D-NMR. A typical decisive feature for  $\alpha$  configuration was irradiation of H2' $\beta$  at the  $\beta$  site of the glycon which resulted in strong NOE enhancements in H1' for both compounds and in H3' for compound 13. For both compounds strong NOE enhancements were found in H2' $\beta$  when H1' or H3' were irradiated. The assignment of the H2' protons in 10 was confirmed by irradiation of H2' $\alpha$  which resulted in NOE enhancement in H4' (5%). Z configuration and N1 glycosylation were proven by NOE enhancements in the phenyl proton when H1' was irradiated (10, 4% and 13, 4%). Besides, this NOE contact between H1' and the aromatic protons indicated a pronounced preference for syn conformation around the glycosidic bond.

No activity was found when the compounds **7**, **9**, **10** and **12-15** were tested against HIV-1 (HTLV-IIIB) in MT-4 cells or against HSV-1 (McIntyre) in rabbit cornea cells at non-toxic concentrations.

#### EXPERIMENTAL

The <sup>13</sup>C- and <sup>1</sup>H-NMR spectra were recorded on a Bruker AC 250 FT and on a Varian UNITY 500 NMR spectrometer. Mass spectra (MS) were recorded using electron ionization (EI) on a Varian Mat 311A spectrometer and fast atom bombardment (FAB) on a Kratos MS 50 spectrometer.

Methyl 5-azido-2,5-dideoxy-3-O-(4-methylbenzoyl)- $\alpha$ -D-erythro-pentofuranoside (4 $\alpha$ ) and its  $\beta$  anomer 4 $\beta$ . Carbon tetrabromide (33.6 g, 101 mmol) was added to a mixture of methyl 2-deoxy-D-erythro-pentofuranoside 2<sup>10,11</sup> (10.0 g, 67.5 mmol), triphenyl phosphine (23.0 g, 88 mmol) and NaN<sub>3</sub> (13.4 g, 200 mmol) in anhydrous N,Ndimethylformamide (500 ml). The mixture was stirred for 7 days at room temperature. The solvent was removed in vacuo and anhydrous diethyl ether (200 ml) was added and the insoluble salts were removed by filtration. The solvent was evaporated under reduced pressure and the residue chromatographed on a silica gel column with ethyl acetate and petroleum ether (1:1, v/v), to obtain 6 g (51%) of methyl 5-azido-2,5-dideoxy-D-erythropentofuranoside 3 as a yellow oil. To a stirred solution of 3 (6.0 g, 34.5 mmol) in anhydrous pyridine (75 ml) was slowly added 4-methylbenzoyl chloride (5.4 g, 35 mmol) at 0°C. The temperature was allowed to increase to room temperature and stirring was continued for 16 h. The reaction mixture was poured into crushed ice and extracted with chloroform  $(2 \times 100 \text{ ml})$ . The combined extracts were washed with a saturated aqueous solution of NaHCO<sub>3</sub> (3  $\times$  100 ml) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated in vacuo and the residue chromatographed on silica gel with petroleum ether and diethyl ether (9:1, v/v) to obtain pure anomers of 4.

**Compound 4** $\alpha$ : Yield 4.0 g (40%), mp 85-87°C. Anal. calcd. for C<sub>14</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>: C 57.72; H 5.88; N 14.42; Found: C 57.54; H 5.79; N 14.01. FAB MS *m*/*z* 292 (M + H<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 250 MHz):  $\delta$  2.17 (1H, dd, J = 1.4, 14.6 Hz, H2' $\alpha$ ), 2.39 (3H, s, CH<sub>3</sub>), 2.48 (1H, m, H2'β), 3.40 (3H, s, OCH<sub>3</sub>), 3.58 (2H, m, H5'), 4.22 (1H, q, J = 3.6 Hz, H4'), 5.19 (2H, m, H1', H3'), 7.22, 7.92 (4H, 2xd, J = 8.0 Hz, H<sub>Arom</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 62.9 MHz): δ 21.43 (CH<sub>3</sub>), 38.95 (C2'), 52.24 (C5'), 54.82 (OCH<sub>3</sub>), 74.83 (C3'), 81.98 (C4'), 104.91 (C1'), 126.81, 128.92, 129.58, 143.78 (C<sub>Arom</sub>), 166.35 (C=O). **Compound 4**β: Yield 3.0 g (30%), oil. Anal. calcd. for C<sub>14</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>: C 57.72; H 5.88; N 14.42. Found: C 57.86; H 5.87; N 13.98. FAB MS *m*/*z* 292 (M + H<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 250 MHz): δ 2.35 (4H, m, H2', CH<sub>3</sub>), 2.47 (1H, ddd, J = 2.3, 7.2, 14.1 Hz, H2'), 3.42 (3H, s, OCH<sub>3</sub>), 3.49 (2H, m, H5'), 4.29 (1H, m, H4'), 5.21 (1H, dd, J = 2.4, 5.3 Hz, H1'), 5.35 (1H, m, H3'), 7.22, 7.88 (4H, 2xd, J = 8.1 Hz, H<sub>Arom</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 62.9 Hz): δ 21.38 (CH<sub>3</sub>), 38.89 (C2'), 53.97 (C5'), 55.26 (OCH<sub>3</sub>), 75.56 (C3'), 83.17 (C4'), 105.74 (C1'), 126.58, 128.92, 129.46, 143.88 (C<sub>Arom</sub>), 165.92 (C=O).

(Z)-1-(5-Azido-2,5-dideoxy-3-O-(4-methylbenzoyl)- $\beta$ -D-erythro-pentofuranosyl)-5-(phenylmethylene)-2,4-imidazolidinedione (7) and its  $\alpha$  anomer (8). A mixture of 5-(phenylmethylene)-2,4-imidazolidinedione 6 (1.5 g, 8 mmol), anhydrous (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> (0.04 mmol) and 1,1,1,3,3,3-hexamethyldisilazane (60 ml) was refluxed overnight. The clear solution obtained was cooled and the solvent was evaporated *in vacuo* to give the silylated compound as a pale yellow oil. A solution of the sugar 4 $\alpha$  (1.57 g, 5.4 mmol) in anhydrous MeCN (30 ml) was added to a stirred solution of the silylated compound in anhydrous MeCN (20 ml) and the mixture was cooled to -50°C. A solution of trimethylsilyl trifluoromethanesulfonate (1.08 ml, 6 mmol) in anhydrous MeCN (10 ml) was added dropwise during 5 min at -50°C and the mixture was stirred overnight at -30°C. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (200 ml), washed with cold saturated aqueous NaHCO<sub>3</sub> (200 ml), water (2 × 100 ml) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The mixture was concentrated *in vacuo* and the residue was chromatographed on silica gel with CHCl<sub>3</sub> to afford compounds 7 and 8.

**Compound 7:** Yield 0.5 g (21%), white foam, FAB MS (CHCl<sub>3</sub> + 1% CH<sub>3</sub>COOH in 3nitrobenzylalcohol) 448 (M + H<sup>+</sup>). <sup>1</sup>H NMR (DMSO- $d_6$ , 250 MHz):  $\delta$  2.23 (1H, ddd, J = 2.3, 6.4, 14.0 Hz, H2'), 2.34 (3H, s, CH<sub>3</sub>), 3.16 (1H, m, H-2'), 3.33 (1H, dd, J = 4.2, 12.9 Hz, H5'), 3.56 (1H, dd, J = 8.1, 12.9 Hz, H5'), 3.97 (1H, m, H4'), 5.30 (1H, dd, J = 2.9, 5.8 Hz, H3'), 5.59 (1H, t, J = 7.2 Hz, H1'), 6.70 (1H, s, =CH), 7.23-7.56 (9H, m, H<sub>Arom</sub>), 11.64 (1H, s, NH). <sup>13</sup>C NMR (DMSO- $d_6$ , 62.9 MHz):  $\delta$  21.03 (CH<sub>3</sub>), 32.64 (C2'), 51.31 (C5'), 74.99 (C3'), 82.25 (C4'), 84.27 (C1'), 111.16 (=CH), 126.23, 128.44, 128.99, 129.05, 129.09, 129.78, 132.42, 143.87 (C5, C<sub>Arom</sub>), 154.41 (C2), 163.54 (C4), 164.71 (C=O).

**Compound 8:** Yield 0.5 g (21%), white foam, EI MS *m*/*z* (%) 447 (3.6, M<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 250 MHz):  $\delta$  2.72 (1H, m, H2'), 2.98 (1H, td, J = 7.0, 13.7 Hz, H2'), 3.33 (1H, dd, J = 4.7, 13.3 Hz, H5'), 3.52 (1H, dd, J = 3.2, 13.3 Hz, H5'), 4.55 (1H, m, H4'), 5.15 (1H, q, J = 2.7 Hz, H3'), 5.68 (1H, t, J = 7.3 Hz, H1'), 6.83 (1H, s, =CH), 7.26-7.92 (9H, m, H<sub>Arom</sub>). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 62.9 MHz):  $\delta$  21.94 (CH<sub>3</sub>), 35.82 (C2'), 53.68 (C5'), 75.55 (C3'), 83.42 (C4'), 85.65 (C1'), 113.90 (=CH), 128.41, 130.19, 130.53, 130.65, 131.13, 131.43, 131. 96, 134.54, 145.93 (C5, C<sub>Arom</sub>), 156.81 (C2), 166.12 (C4), 168.01 (C=O).

(Z)-1-(5-Azido-2,5-dideoxy- $\beta$ -D-erythro-pentofuranosyl)-5-(phenylmethylene)-2,4imidazolidinedione (9). To a stirred suspension of the protected nucleoside 7 (0.4 g, 0.89 mmol) in anhydrous MeOH (15 ml) was added portionwise NaOMe (0.05 g, 0.9 mmol) in anhydrous MeOH (15 ml) at room temperature and the solution was stirred overnight. After evaporation of the solvent in vacuo, H2O (15 ml) was added and the mixture extracted several times with CH2Cl2 to remove the formed ester during deprotection. To the resulting aqueous solution was added an ion exchange resin (Dowex  $50W \times 2$ , H<sup>+</sup>-form), previously washed with MeOH. After stirring for 5 min, the solution was filtered and evaporated *in vacuo* and the residue was chromatographed on silica gel with the gradient 2-5% MeOH in CHCl<sub>3</sub> to give 0.25 g (85%) of 9 as a white foam, EI MS m/z (%) 329 (4, M<sup>+</sup>). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 500 MHz):  $\delta$  1.95 (1H, ddd, J = 5.0, 8.0, 14.5 Hz, H2' $\alpha$ ), 2.94 (1H, m, H2' $\beta$ ), 3.26 (1H, m, H5'), 3.44 (1H, dd, J = 7.6, 12.9 Hz, H5'), 3.65 (1H, td, J = 3.9, 8.1 Hz, H4'), 4.34 (1H, td, J = 4.8, 7.1 Hz, H3'), 5.60 (1H, dd, J = 6.1, 7.8 Hz, H1'), 6.74 (1H, s, =CH), 7.29-7.42 (5H, m,  $H_{Arom}$ ). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 125.7 MHz): δ 37.65 (C2'), 53.07 (C5'), 72.89 (C3'), 85.61 (C1'), 86.50 (C4'), 113.63 (=CH), 129.78, 129.90, 130.37, 131.30, 134.09 (C5, C<sub>Arom</sub>), 156.12 (C2), 165.83 (C4).

(Z)-1-(5-Azido-2,5-dideoxy- $\alpha$ -D-*erythro*-pentofuranosyl)-5-(phenylmethylene)-2,4imidazolidinedione (10). The protected nucleoside 8 (0.4 g, 0.89 mmol) was treated similarly as described in the preparation of **9**. Purification by column chromatography on silica gel with the gradient 2-5% MeOH in CHCl<sub>3</sub> gave 0.26 g (88%) of **10** as a white foam. FAB MS (CHCl<sub>3</sub> + 1% CH<sub>3</sub>COOH in 3-nitrobenzylalcohol) 330 (M + H<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  2.44 (1H, m, H2' $\beta$ ), 2.65 (1H, m, H2' $\alpha$ ), 3.25 (1H, dd, J = 4.8, 13.1 Hz, H5'), 3.41 (1H, dd, J = 3.5, 13.1 Hz, H5'), 4.17 (1H, m, H3'), 4.37 (1H, m, H4'), 4.92 (1H, d, J = 11.3 Hz, 3'-OH), 5.64 (1H, dd, J = 3.4, 9.1 Hz, H1'), 6.97 (1H, s, =CH), 7.26-7.44 (5H, m, H<sub>Arom</sub>), 9.39 (1H, s, NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125.7 MHz):  $\delta$  39.06 (C2'), 52.71 (C5'), 73.38 (C3'), 84.55 (C1'), 86.58 (C4'), 115.02 (=CH), 128.68, 128.86, 129.11, 129.14, 131.82 (C5, C<sub>Arom</sub>), 154.98 (C2), 163.29 (C4).

(Z)-1-(5-Amino-2,5-dideoxy-β-D-*erythro*-pentofuranosyl)-5-(phenylmethylene)-2,4imidazolidinedione (11). Anhydrous tin(II)chloride (200 mg, 0.88 mmol) was added to a solution of 9 (220 mg, 0.67 mmol) in methanol (25 ml) and the mixture was stirred at room temperature for one week. The solvent was evaporated *in vacuo*. The residue was chromatographed on silica gel with the gradient 2-10% MeOH in CHCl<sub>3</sub> to give 190 mg of 9 and 20 mg (10%) of 11 as a white solid, mp 198-200°C, FAB MS (DMSO + 1% CF<sub>3</sub>COOH in glycerol) 304 (M + H<sup>+</sup>). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 250 MHz): δ 2.20 (1H, ddd, J = 4.2, 7.7, 13.6 Hz, H2'), 3.01 (1H, td, J = 6.8, 13.5 Hz, H2'), 3.29 (2H, m, H5'), 3.95 (1H, td, J = 4.2, 7.9 Hz, H4'), 4.50 (1H, td, J = 3.6, 7.1 Hz, H3'), 5.83 (1H, t, J = 7.1 Hz, H1'), 6.91 (1H, s, =CH), 7.45-7.54 (5H, m, H<sub>Arom</sub>). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 62.9 MHz): δ 37.86 (C2'), 42.50 (C5'), 73.20 (C3'), 83.49 (C1'), 86.27 (C4'), 113.56 (=CH), 129.86, 129.98, 130.26, 131.10, 134.00 (C5, C<sub>Arom</sub>), 156.38 (C2), 165.60 (C4).

(Z)-1-(5-O-Acetyl-2,3-dideoxy-3-phthalimido- $\beta$ -D-erythro-pentofuranosyl)-5-(phenylmethylene)-2,4-imidazolidinedione (12) and its  $\alpha$  anomer (13). A mixture of 5-(phenylmethylene)-2,4-imidazolidinedione 6 (1.5 g, 8 mmol), anhydrous (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> (0.04 mmol) and 1,1,1,3,3,3-hexamethyldisilazane (60 ml) was refluxed overnight. The clear solution obtained was cooled and the solvent was evaporated *in vacuo* to give the silylated compound as a pale yellow oil. A solution of the sugar 5<sup>11</sup> (1.5 g, 4.3 mmol) in anhydrous MeCN (30 ml) was added to a stirred solution of the silylated compound in anhydrous MeCN (20 ml) and the mixture was cooled to -50°C. A solution of trimethylsilyl trifluoromethanesulfonate (0.85 ml, 4.4 mmol) in anhydrous MeCN (10 ml)

#### **HYDANTOIN 2'-DEOXYNUCLEOSIDES**

was added dropwise during 5 min at -50°C and the mixture was stirred overnight at -30°C. The reaction mixture was diluted with  $CH_2Cl_2$  (200 ml), washed with cold saturated aqueous NaHCO<sub>3</sub> (200 ml), water (2 × 100 ml) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The mixture was concentrated *in vacuo* and the residue was chromatographed on silica gel with CHCl<sub>3</sub> to afford compounds **12** and **13**.

**Compound 12:** Yield 0.92 g (45%), white foam. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 250 MHz):  $\delta$  2.00 (3H, s, CH<sub>3</sub>), 2.74-2.98 (2H, m, H2'), 4.15-4.33 (3H, m, H-4', H5'), 5.18 (1H, td, J = 8.0, 9.7 Hz, H3'), 5.90 (1H, dd, J = 4.8, 8.3 Hz, H1'), 6.92 (1H, s, =CH), 7.27-7.84 (9H, m, H<sub>Arom</sub>), 8.86 (1H, s, NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 62.9 MHz):  $\delta$  20.54 (CH<sub>3</sub>), 31.61 (C2'), 49.77 (C3'), 64.01 (C5'), 77.82 (C4'), 83.96 (C1'), 113.91 (=CH), 123.29, 128.68, 128.97, 129.03, 129.08, 131.51, 132.27, 134.12 (C5, C<sub>Arom</sub>), 153.38 (C2), 163.39 (C4), 167.49, 170.55 (2 C=O).

**Compound 13:** Yield 0.90 g (44%), white foam. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 250 MHz):  $\delta$  1.96 (3H, s, CH<sub>3</sub>), 2.34 (1H, m, H2'), 3.90 (1H, dd, J = 3.2, 11.9 Hz, H2'), 4.02 (1H, dd, J = 4.8, 12.4 Hz, H5'), 4.18 (1H, dd, J = 3.0, 12.3 Hz, H5'), 4.52 (1H, m, H3'), 5.23 (1H, m, H4'), 5.59 (1H, dd, J = 6.9, 8.3 Hz, H1'), 6.88 (1H, s, =CH), 7.26-7.87 (9H, m, H<sub>Arom</sub>), 8.83 (1H, s, NH). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 62.9 MHz):  $\delta$  20.52 (CH<sub>3</sub>), 30.27 (C-2'), 50.27 (C3'), 62.99 (C5'), 75.71 (C4'), 83.42 (C1'), 113.31 (=CH), 123.41, 128.66, 128.92, 129.05, 129.45, 131.50, 132.49, 134.19 (C5, C<sub>Arom</sub>), 153.73 (C2), 163.28 (C4), 167.55, 170.43 (2 C=O).

(Z)-1-(3-Amino-2,3-dideoxy- $\beta$ -D-*erythro*-pentofuranosyl)-5-(phenylmethylene)-2,4imidazolidinedione (14): A 33% solution of MeNH<sub>2</sub> in absolute EtOH (20 ml) was added to a stirred suspension of compound 12 (0.55 g, 1.15 mmol) in abs. EtOH (10 ml) at room temperature and stirring was continued overnight. The solvent was evaporated under reduced pressure. The residue was chromatographed on silica gel using CHCl<sub>3</sub>/MeOH (9:1) as eluent to give 0.3 g (86%) of 14 as a white solid, mp 150-152°C, FAB MS (DMSO + 1% CH<sub>3</sub>COOH in 3-nitrobenzylalcohol) 304 (M + H<sup>+</sup>). Anal. calc. for C<sub>15</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>·H<sub>2</sub>O: C, 56.07; H, 5.96; N, 13.08. Found: C, 56.28; H, 5.48; N, 13.16. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 500 MHz):  $\delta$  1.81 (1H, m, H2'), 2.70 (1H, m, H2'), 3.30 (1H, m, H3'), 3.43 (2H, m, H4', H5'), 3.56 (1H, dd, J = 4.0, 11.4 Hz, H5'), 4.86 (2H, s, NH<sub>2</sub>), 5.47 (1H, dd, J = 4.8, 8.2 Hz, H1'), 6.63 (1H, s, =CH), 7.34-7.48 (5H, m, H<sub>Arom</sub>). <sup>13</sup>C NMR (DMSO- $d_6$ , 125.7 MHz):  $\delta$  37.58 (C2'), 51.96 (C3'), 62.25 (C5'), 83.25 (C1'), 86.34 (C4'), 110.13 (=CH), 128.37, 128.49, 129.16, 130.32, 132.81 (C5, C<sub>Arom</sub>), 155.29 (C2), 164.85 (C4).

(Z)-1-(3-Amino-2,3-dideoxy- $\alpha$ -D-*erythro*-pentofuranosyl)-5-(phenylmethylene)-2,4imidazolidinedione (15). The protected nucleoside 13 (0.3 g, 1.15 mmol) was treated similarly as described for the preparation of 14. Purification by column chromatography on silica gel with CHCl<sub>3</sub>/MeOH (90:10) as eluent gave 0.32 g (92%) of 15 as a white foam.

Anal. calc. for  $C_{15}H_{17}N_3O_4 \cdot 1.5H_2O$ : C, 54.84; H, 6.10; N, 12.72. Found: C, 55.24; H, 5.84; N, 12.48. <sup>1</sup>H NMR (DMSO- $d_6$ , 250 MHz):  $\delta$  2.46 (2H, m, H2'), 3.10 (1H, dd, J = 7.8, 15.4 Hz, H3'), 3.30 (1H, dd, J = 4.6, 11.8 Hz, H5'), 3.43 (1H, m, H5'), 3.84 (1H, m, H4'), 4.94 (1H, s, 5'-OH), 5.09 (2H, s, NH<sub>2</sub>), 5.37 (1H, t, J = 7.0 Hz, H1'), 6.61 (1H, s, =CH), 7.25-7.44 (5H, m, H<sub>Arom</sub>). <sup>13</sup>C NMR (DMSO- $d_6$ , 62.9 Hz):  $\delta$  37.02 (C2'), 52.37 (C3'), 61.19 (C5'), 83.86 (C1'), 86.21 (C4'), 109.78 (=CH), 128.28, 128.48, 129.08, 130.78, 132.89 (C5, C<sub>Arom</sub>), 157.10 (C2), 165.61 (C4).

Acknowledgement: This paper was supported by Danish Ministry of Education, Danish Medical Research Council and Egyptian Ministry of Higher Education.

#### REFERENCES

- 1. El-Barbary, A. A.; Khodair, A. I.; Pedersen, E. B. J. Org. Chem. in press.
- 2. Neenan, J. P.; Rohde, W. J. Med. Chem. 1973, 16, 580.
- 3. Cheng, Y. C.; Prusoff, W. H. Biochemistry 1974, 13, 1179.
- 4. Cheng, Y. C.; Prusoff, W. H. Biochemistry 1973, 12, 2612.
- Cheng, Y. C.; Neenan, J. P.; Goz, B.; Ward, D. C.; Prusoff, W. H. J. Virol. 1975, 15, 1284.
- Cheng, Y. C.; Neenan, J. P.; Goz, B.; Ward, D. C.; Prusoff, W. H. An. N. Y. Acad. Sci. 1975, 255, 332.
- Prusoff, W. H.; Ward, D. C.; Lin, T. S.; Chen, M. S.; Shiau, G. T.; Chai, C.; Lentz, E.; Capizzi, R.; Idriss, J.; Ruddle, N. H.; Black, F. L.; Albert, D. M.; Bhatt,

P. N.; Hsiung, G. C.; Strickland, S.; Cheng, Y. C. An. N. Y. Acad. Sci. 1977, 284, 335.

- 8. Lin, T. S.; Prusoff, W. H. J. Med. Chem. 1978, 21, 109.
- 9. Fischer, E. Ber. Dtsch. Chem. Ges. 1945, 28, 1145.
- 10. Hata, T.; Yamamoto, I.; Sekine, M. Chem. Lett. 1975, 977.
- Motawia, M. S.; Wengel, J.; Abdel-Megied, A. E. S.; Pedersen, E. B. Synthesis 1989, 384.

Received 6/26/93 Accepted 11/11/93